Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection for Early Gastric Cancer

Endoscopic Submucosal Dissection Combine With Laparoscopic Regional Lymph Node Dissection:a New Therapy for Early Gastric Cancer

Status

UNKNOWN

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02325999

Enrollment

200

Registered

2014-12-25

Start date

2013-12-31

Completion date

2019-12-31

Last updated

2014-12-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Gastric Cancer

Keywords

Endoscopic Submucosal Dissection, Laparoscopic Regional Lymph node Dissection, early gastric cancer, Disease-free survival

Brief summary

The purpose of this study is to determine whether Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection for early gastric cancer can improve Disease-free survival ？

Detailed description

Patients with early stage of gastric cancer(T1a/T1bN0M0,NCCN2014.V1) will depart into two group randomized double-blind, then experimental group accept Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection ,and control group accept Endoscopic Submucosal Dissection only.The follow-up time is from operation to recrudescence.

Interventions

PROCEDUREESD AND LRLD

A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* cT1a：ulcer（+）and lesion diameter\>3cm and differentiated type. Any ulcer and lesion diameter d\>2cm and poorly differentiated type. * cT1b: Submucosal injection (+)

Exclusion criteria

* metastasis * recrudescence

Design outcomes

Primary

Measure	Time frame	Description
DFS	Five years	Follow-up Disease-free Survival

Countries

China

Contacts

Primary ContactHua MENG

Meng.doctor@gmail.com+8613488882358

Backup ContactQiu-yue ZHANG

zhangqiu3660@icloud.com+8615810110118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026